Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy

Abstract

Hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy (RCM) present a high risk for sudden cardiac death in pediatric patients. The aim of this study was to identify disease-associated genetic variants in Japanese patients with pediatric HCM and RCM. We analyzed 67 cardiomyopathy-associated genes in 46 HCM and 7 RCM patients diagnosed before 16 years of age using a next-generation sequencing system. We found that 78% of HCM and 71% of RCM patients carried disease-associated genetic variants. Disease-associated genetic variants were identified in 80% of HCM patients with a family history and in 77% of HCM patients with no apparent family history (NFH). MYH7 and/or MYBPC3 variants comprised 76% of HCM-associated variants, whereas troponin complex-encoding genes comprised 75% of the RCM-associated variants. In addition, 91% of HCM patients with implantable cardioverter-defibrillators and infant cases had NFH, and the 88% of HCM patients carrying disease-associated genetic variants were males who carried MYH7 or MYBPC3 variants. Moreover, two disease-associated LAMP2, one DES and one FHOD3 variants, were identified in HCM patients. In this study, pediatric HCM and RCM patients were found to carry disease-associated genetic variants at a high rate. Most of the variants were in MYH7 or MYPBC3 for HCM and TNNT2 or TNNI3 for RCM.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085–92.

    Article  PubMed  Google Scholar 

  2. 2.

    Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242–55.

    Article  PubMed  Google Scholar 

  3. 3.

    Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013;382:1889–97.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Maron BJ, Rowin EJ, Casey SA, Maron MS. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol. 2016;1:98–105.

    Article  PubMed  Google Scholar 

  5. 5.

    Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation. 2012;126:1237–44.

    Article  PubMed  Google Scholar 

  6. 6.

    Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res. 2011;108:743–50.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Kimura A. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J. 2008;72:A38–48.

    Article  PubMed  Google Scholar 

  8. 8.

    Ingles J, Sarina T, Yeates L, Hunt L, Macciocca I, McCormack L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972–7.

    Article  PubMed  Google Scholar 

  9. 9.

    McNally EM, Puckelwartz MJ. Genetic variation in cardiomyopathy and cardiovascular disorders. Circ J. 2015;79:1409–15.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. 10.

    Lopes LR, Syrris P, Guttmann OP, O’Mahony C, Tang HC, Dalageorgou C, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294–301.

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899–908.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. 12.

    Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2:436–41.

    Article  PubMed  CAS  Google Scholar 

  13. 13.

    Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, et al. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail. 2012;18:396–403.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. 14.

    Kaski JP, Syrris P, Burch M, Tome-Esteban MT, Fenton M, Christiansen M, et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart. 2008;94:1478–84.

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Towbin JA. Inherited cardiomyopathies. Circ J. 2014;78:2347–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. 16.

    Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997;16:379–82.

    Article  PubMed  CAS  Google Scholar 

  17. 17.

    Purevjav E, Arimura T, Augustin S, Huby AC, Takagi K, Nunoda S, et al. Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum Mol Genet. 2012;21:2039–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. 18.

    Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J. 2012;76:453–61.

    Article  PubMed  CAS  Google Scholar 

  19. 19.

    Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. 20.

    Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.

    Article  PubMed  CAS  Google Scholar 

  21. 21.

    Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. 22.

    Higasa K, Miyake N, Yoshimura J, Okamura K, Niihori T, Saitsu H, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016;61:547–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. 23.

    Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE. 2012;7:e46688.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. 24.

    Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11:361–2.

    Article  PubMed  CAS  Google Scholar 

  25. 25.

    Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, et al. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum Mutat. 2013;34:57–65.

    Article  PubMed  CAS  Google Scholar 

  26. 26.

    Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. 27.

    Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–81.

    Article  PubMed  CAS  Google Scholar 

  28. 28.

    Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980–5.

    Article  PubMed  CAS  Google Scholar 

  29. 29.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. 31.

    Harada H, Hayashi T, Nishi H, Kusaba K, Koga Y, Koga Y, et al. Phenotypic expression of a novel desmin gene mutation: hypertrophic cardiomyopathy followed by systemic myopathy. J Hum Genet. 2018;63:249–54.

    Article  PubMed  CAS  Google Scholar 

  32. 32.

    Taniguchi K, Takeya R, Suetsugu S, Kan OM, Narusawa M, Shiose A, et al. Mammalian formin fhod3 regulates actin assembly and sarcomere organization in striated muscles. J Biol Chem. 2009;284:29873–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. 33.

    Kimura A. Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet. 2016;61:41–50.

    Article  PubMed  CAS  Google Scholar 

  34. 34.

    Bloemink M, Deacon J, Langer S, Vera C, Combs A, Leinwand L, et al. The hypertrophic cardiomyopathy myosin mutation R453C alters ATP binding and hydrolysis of human cardiac beta-myosin. J Biol Chem. 2014;289:5158–67.

    Article  PubMed  CAS  Google Scholar 

  35. 35.

    Sommese RF, Sung J, Nag S, Sutton S, Deacon JC, Choe E, et al. Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human beta-cardiac myosin motor function. Proc Natl Acad Sci USA. 2013;110:12607–12.

    Article  PubMed  Google Scholar 

  36. 36.

    Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–14.

    Article  PubMed  CAS  Google Scholar 

  37. 37.

    Greber-Platzer S, Marx M, Fleischmann C, Suppan C, Dobner M, Wimmer M. Beta-myosin heavy chain gene mutations and hypertrophic cardiomyopathy in Austrian children. J Mol Cell Cardiol. 2001;33:141–8.

    Article  PubMed  CAS  Google Scholar 

  38. 38.

    Gruen M, Gautel M. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C. J Mol Biol. 1999;286:933–49.

    Article  PubMed  CAS  Google Scholar 

  39. 39.

    Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. Genome Biol. 2016;17:241.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. 40.

    Meurs KM, Norgard MM, Ederer MM, Hendrix KP, Kittleson MD. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. Genomics. 2007;90:261–4.

    Article  PubMed  CAS  Google Scholar 

  41. 41.

    Ripoll Vera T, Monserrat Iglesias L, Hermida Prieto M, Ortiz M, Rodriguez Garcia I, Govea Callizo N, et al. The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans. Int J Cardiol. 2010;145:405–7.

    Article  PubMed  Google Scholar 

  42. 42.

    Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–57.

    Article  PubMed  CAS  Google Scholar 

  43. 43.

    Ostman-Smith I, Wettrell G, Keeton B, Holmgren D, Ergander U, Gould S, et al. Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J. 2008;29:1160–7.

    Article  PubMed  Google Scholar 

  44. 44.

    Emery MJ, Krous HF, Nadeau-Manning JM, Marck BT, Matsumoto AM. Serum testosterone and estradiol in sudden infant death. J Pediatr. 2005;147:586–91.

    Article  PubMed  CAS  Google Scholar 

  45. 45.

    Gomes AV, Liang J, Potter JD. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem. 2005;280:30909–15.

    Article  PubMed  CAS  Google Scholar 

  46. 46.

    Yumoto F, Lu QW, Morimoto S, Tanaka H, Kono N, Nagata K, et al. Drastic Ca2+sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem Biophys Res Commun. 2005;338:1519–26.

    Article  PubMed  CAS  Google Scholar 

  47. 47.

    Arimura T, Takeya R, Ishikawa T, Yamano T, Matsuo A, Tatsumi T, et al. Dilated cardiomyopathy-associated FHOD3 variant impairs the ability to induce activation of transcription factor serum response factor. Circ J. 2013;77:2990–6.

    Article  PubMed  CAS  Google Scholar 

  48. 48.

    Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med. 2017;9:20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. 49.

    Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol. 2016;68:2871–86.

    Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Yukiko Ueda and Chinami Sonobe for their excellent technical assistance with respect to NGS and Sanger sequencing. We are also grateful to the following doctors for blood sampling and clinical examinations: Tsuguya Sakamoto (Hanzomon Hospital, Tokyo, Japan), Sachio Kawai (Juntendo University, Tokyo, Japan), Hirofumi Nishi (Kurume University, Fukuoka, Japan), Keiko Kawano, Seigo Okada and Masahiko Harada (Yamaguchi University, Yamaguchi, Japan), Yoshimiki Kiyohara (Kobe University, Kobe, Japan), Takeshi Tana (Ryukyu University, Okinawa, Japan), Kazuhiro Mori (Tokushima University, Tokushima, Japan), Hitoshi Koito (Kansai Medical University, Hyogo, Japan), Yo Niida (Kanazawa Medical University, Kanazawa, Japan), Tdaaki Abe and Kanae Noritake (National Cerebral and Cardiovascular Center, Osaka, Japan), Atsuhito Takeda (Hokkaido University, Hokkaido, Japan), Junji Toyama (Nagoya Heart Center, Aichi, Japan), Takuro Arimura (Kagoshima University, Kagoshima, Japan), Taisuke Ishikawa (Nagasaki University, Nagasaki, Japan), Hironori Murakami (Teine Keijinkai Hospital, Hokkaido, Japan), and Fukiko Ichida (Toyama University, Toyama, Japan). This research was supported by Japan Society for the Promotion of Science KAKENHI grant number 26460407 (T.H.), 17K08684 (T.H.), 15K15095 (A.K.) and 16H05296 (A.K.), a grant from THE INSTITUTE OF SEIZON AND LIFE SCIENCES (T.H), and Nanken-Kyoten, TMDU.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Takeharu Hayashi or Akinori Kimura.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hayashi, T., Tanimoto, K., Hirayama-Yamada, K. et al. Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy. J Hum Genet 63, 989–996 (2018). https://doi.org/10.1038/s10038-018-0479-y

Download citation

Further reading

Search

Quick links